KIT and neoplasm: Lin et al. [28] found a correlation between exon 10 mutations of the KIT gene and tumor invasiveness with poor prognosis, whereas exon 11 mutations were associated with better disease-free prognosis [28] attributed to a more favorable response to imatinib [247].